Funding for this research was provided by:
Text and Data Mining valid from 2018-03-27
Received: 14 September 2017
Accepted: 27 February 2018
First Online: 27 March 2018
Ethics approval and consent to participate
: This study was conducted in accordance with the International Conference on Harmonization good clinical practice guideline and the Declaration of Helsinki. Approval of an institutional ethics review board and voluntary written informed patient consent were obtained prior to initiation of study procedures.
: Not applicable.
: DvdH has received consulting fees from AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB and is director of Imaging Rheumatology B.V. JS has received research grants, consulting fees, and speaker’s fees from AbbVie, Merck, Pfizer, and UCB. WPM has received research grants and consulting fees from AbbVie, Amgen, Eli Lilly, Janssen, Merck, Novartis, Pfizer, SYNARC, and UCB and is chief medical officer of CaRE Arthritis. RGL has received consulting or advisory board fees from AbbVie, BioClinica, Janssen, Parexel, and UCB. SC, MH, JKA, and ALP are full-time employees of AbbVie and may hold stock and/or options.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.